ArticleMovement disorders clinical practice2023
A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease.
Article in Movement disorders clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.Arquivos de neuro-psiquiatria · 2025Guideline
- Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2024Trial
- The role of botulinum toxin in the multimodal management of pain in Parkinson's disease: a scoping review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Therapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials.Acta neurologica Belgica · 2026Review
- Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review.Drug and alcohol review · 2026Review
- The Use of Cannabis-Based Medicine in Selected Neurological Disorders.Current topics in behavioral neurosciences · 2026Review
- Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey.Parkinson's disease · 2025Article
- Advice to People with Parkinson's in My Clinic: Cannabis.Journal of Parkinson's disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pain is common in Parkinson's disease (PD), but effective therapies are limited. Objectives: To determine the maximum tolerated dose (MTD) and safety of formulations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain in PD. Methods: In this phase 1b, double-blind, randomized, single-center study, participants were randomized to three formulations of THC/CBD (18:0, 10:10, and 1:20). The MTD, adverse events (AE), and tolerability are described for each formulation. Results: Eight participants were randomized. The MTD was similar among groups (0.8-0.9 mL/daily), and there were no serious AE or study drop-outs. The most common AE were drowsiness and dizziness (three participants). Epworth sleepiness scale scores were higher in the high CBD formulation (1:20). Conclusions: In patients with pain and PD, mixed formulations of THC/CBD were tolerated with no serious AE. Considering the safety profile, future phase II studies should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.